We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Patient Specific Talus Spacer Treats Avascular Necrosis

By HospiMedica International staff writers
Posted on 04 Mar 2021
Image: The 3D printed Patient Specific Talus Spacer (Photo courtesy of Additive Orthopaedics)
Image: The 3D printed Patient Specific Talus Spacer (Photo courtesy of Additive Orthopaedics)
An additively manufactured patient specific implant allows patients suffering from avascular necrosis (AVN) to regain motion and reduce pain in the ankle.

The Additive Orthopaedics (Little Silver, NJ, USA) Patient Specific Talus Spacer is a three dimension (3D) printed implant that is designed to provide a joint-sparing alternative to other surgical interventions commonly used in late-stage AVN that may disable motion of the ankle joint. Constructed of a porous lattice structure in order to support bony in-growth, the advanced talus implant includes complex geometries that lead to enhanced osteointegration, which are not possible with traditional manufacturing processes.

The Patient Specific Talus Spacer is 3D printed for each patient individually, modeled from a computed tomography (CT) scan, and is fitted to the patient's specific anatomy. During the replacement surgery, the patient's talus bone is removed and replaced with the implant, which is made from cobalt chromium alloy. While fusion may become necessary in the future (should the condition worsen), the Additive Orthopaedics Talus Spacer provides a joint-sparing procedure, as it allows the patient to retain motion in the ankle joint.

“Avascular necrosis of the talus is extremely painful and debilitating for these patients. The Patient Specific Talus Spacer is another example of how 3D printed devices can improve the standard of care,” said Greg Kowalczyk, President of Additive Orthopaedics. “Surgical treatment options are below-the-knee amputation or joint fusion, which results in loss of motion of the ankle, and can have poor outcomes.”

AVN of the ankle joint is a serious and progressive condition that causes death of bone tissue stemming from a lack of blood supply to the area. It is often caused by a sudden injury--such as a broken bone or a dislocated joint--or sustained damage to the tissue that develops over time, causing the damaged bone to turn necrotic. When a joint is affected, such as the ankle, the cartilage also deteriorates, leading to arthritis and pain. Late-stage AVN of the ankle may result in the talus partially or fully collapsing.

Related Links:
Additive Orthopaedics

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Antimicrobial Mat
MULTIMAT
New
VTE Prevention System
Flowtron ACS900

Channels

Critical Care

view channel
The intelligent wound dressing consists of a granular hydrogel (Photo courtesy of Apoorv Singh/ETH Zurich)

Intelligent Wound Dressing Reduces Inflammation and Promotes Healing

Chronic wounds, especially those caused by diabetes or circulatory disorders, are a widespread medical problem that burden healthcare systems. Patients often suffer from open skin lesions that fail to... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more